Connect with us

Artificial Intelligence

Biocept Reports Second Quarter 2019 Financial Results

Vlad Poptamas

Published

on

Reading Time: 4 minutes

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three and six months ended June 30, 2019, and provides an update on its business progress.

“I’m pleased to report another quarter of strong performance with revenues increasing 45% over the prior-year quarter, as we continue to execute on our new commercial strategy,” said Michael Nall, President and CEO of Biocept.  “Growth was driven by a 26% year-over-year increase in commercial samples, as we focused our commercial efforts on segments of the liquid biopsy oncology market where Target Selector™ can help the most patients, namely in prostate, breast, and lung cancers. Most importantly, we are helping more patients as our billable samples accessioned per sales day entering the third quarter increased approximately 50% from the beginning of the year.

“We have now launched two tumor-specific panels developed in collaboration with Thermo Fisher Scientific,” he added.  “These products, Target Selector™ NGS Lung Panel and Target Selector™ NGS Breast Panel, combine Thermo Fishers’ state-of-the-art Ion Torrent™ next-generation sequencing (NGS) platform with our CLIA laboratory and commercial infrastructure, as well as our expertise in blood sample preservation and DNA/RNA isolation.  Biocept is the only commercial liquid biopsy company offering both circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) analysis with both single-gene and multi-gene offerings.

“I’m also pleased to report that our initiative with Prognos has advanced to the next phase as we are beginning to supply them with de-identified information in real time.  We believe this partnership will allow us to commercialize data generated from our liquid biopsy testing, with Prognos applying its artificial intelligence technology to its repository of more than 20 billion laboratory records to help life science and pharmaceutical companies develop and market targeted therapies.  We are pleased to be the first liquid biopsy company to strike a partnership with Prognos,” he concluded.

Review of Second Quarter and Recent Highlights

Commercial Business

  • Launched Target Selector™ NGS Lung Panel and Target Selector™ NGS Breast Panel, the Company’s first two multi-gene liquid biopsy panels, differentiating Biocept as the only commercial liquid biopsy provider of single-biomarker testing, tumor-specific panels and CTCs analysis. The NGS Panels run on Thermo Fisher Scientific’s Ion Torrent™ NGS platform and are being marketed to physicians and researchers for the detection and monitoring of actionable biomarkers associated with these tumor-specific cancers.

Commercial Agreements

  • Announced an agreement with Beacon Laboratory Benefit Solutions, Inc. designating Biocept as a BeaconLBS® Lab-of-Choice. Beacon Laboratory is a nationally recognized provider of laboratory benefit management technology solutions to U.S.-based health and managed care companies, and the designation increases patient access to Biocept’s liquid biopsy testing platforms.

Intellectual Property

  • Awarded a patent in China covering methods and devices for the capture of rare cells of interest, including CTCs, that are shed into the bloodstream by solid tumors in which an antibody or mixture of antibodies and a microchannel are used for cell capture, detection and analysis. This patent covers the use of any biological sample type of interest.

Second Quarter Financial Results

Revenues for the second quarter of 2019 were $1.2 million, a 45% increase from $822,000 for the second quarter of 2018.  Revenues for the second quarter of 2019 included $1.1 million in commercial test revenue, $45,000 in development services test revenue, $28,000 in revenue for Target Selector RUO kits, which were commercially launched in early 2019, and CEE-Sure blood collection tubes.  Revenues for the second quarter of 2018 included $771,000 in commercial test revenue and $51,000 in development services test revenue.

Biocept accessioned 1,066 commercial samples during the second quarter of 2019, a 26% increase compared with 849 commercial samples accessioned during the second quarter of 2018.  The Company accessioned 1,211 billable samples in the second quarter of 2019, compared to 996 billable samples for the second quarter of 2018.

Cost of revenues for the second quarters of 2019 and 2018 was unchanged at $2.7 million, as we continued to leverage the fixed components of our costs.

Research and development (R&D) expenses for the second quarter of 2019 were $1.1 million compared with $1.0 millionfor the prior-year period, with the increase primarily due to the development and validation of the recently launched Target Selector™ NGS Lung and Target Selector™ NGS Breast liquid biopsy panels, as well as investments in automation.  General and administrative (G&A) expenses for the second quarters of 2019 and 2018 were unchanged at $1.7 million.  As a percentage of revenue, G&A expenses during the quarter were down 67% as compared to the same period last year as the Company continues with its cost containment program. Sales and marketing (S&M) expenses for the second quarter of 2019 were $1.6 million compared with $1.4 million for the second quarter of 2018, with the increase primarily attributed to higher volume and revenue. Despite the increase in costs, S&M expenses as a percentage of revenue were down 39% compared to the same period last year.

Other expenses for the second quarter of 2019 were $1.8 million, which were made up entirely of non-cash warrant inducement expenses associated with recognizing the fair value of the inducement warrants issued in May 2019.

The net loss for the second quarter of 2019 was $7.8 million, inclusive of the previously mentioned non-cash warrant inducement expenses of $1.8 million, or $0.38 per share on 20.5 million weighted-average shares outstanding. This compares with a net loss for the second quarter of 2018 of $6.2 million, or $2.70 per share on 2.3 million weighted-average shares outstanding. The Company conducted a 1-for-30 reverse stock split of its outstanding common stock, which was effective in July 2018.

Six Month Financial Results

Revenues for the first six months of 2019 were $2.2 million, a 36% increase from $1.6 million for the first six months of 2018, and included $2.1 million in commercial test revenues, $87,000 in development services test revenues and $33,000 in revenues for Target Selector RUO kits, which were commercially launched in early 2019, and CEE-Sure blood collection tubes.

Operating expenses for the first six months of 2019 were $14 million, and included cost of revenues of $5.3 million, R&D expenses of $2.4 million, G&A expenses of $3.4 million and S&M expenses of $3.0 million.

The net loss for the first six months of 2019 was $13.8 million, inclusive of the previously mentioned non-cash warrant inducement expenses of $1.8 million, or $0.83 per share on 16.7 million weighted-average shares outstanding.  This compares with a net loss for the first six months of 2018 of $12.5 million, or $5.97 per share, on 2.1 million weighted-average shares outstanding.

Biocept reported cash and cash equivalents as of June 30, 2019 of $12.6 million, compared with $3.4 million as of December 31, 2018.  The increase was due to $17.0 million in net proceeds from equity capital raises conducted in the first quarter of 2019, and $4.9 million from the exercise of common stock warrants in the second quarter of 2019.

 

SOURCE Biocept, Inc.

Hello!


Thank you for visiting my profile and thank you for reading my news and published press release!


There a many things that shape a man, but the carving is done by the hobbies and passions. I've pursued two main careers, professional photography and webdesign, while also keeping a passion for automobiles, technology and games. At PICANTE NEWS, I take care of news editing and press release publishing in se
veral categories and as I've mentioned, during my spare time, I am also a professional photographer with webdesign skills.

My future plans include developing more journalistic skills and start creating investigative journalism. You can find my reports and press release coverages in the following categories:


BANKING/FINANCIAL SERVICES, COMPUTER ELECTRONICS, AUTOMOTIVE, CONTRACTS, ANALYSIS, INTERNET TECHNOLOGY, BIOTECHNOLOGY, BLOCKCHAIN, ACQUISITIONS, RETAIL, and many more.



You can get in touch to discuss interviews or possible article submissions by contacting us.


Let's also connect via social media! You can find me on Facebook or visit my photo portfolio.

Artificial Intelligence

The Use of Artificial Intelligence by Startups and SMEs panel discussion moderated by Dr. Robert Skalina (WH Partners) at TCE2019 Prague

Zoltán Tűndik

Published

on

Reading Time: 2 minutes

 

Leading law expert and tech compliance advisor to moderate the AI-related panel discussion at PICANTE TECH Conference Europe 2019.

 

The future is almost here and there are more and more talks about AI being a key part of our daily life. But, it seems we are not quite there yet as most of the services that are available are not the real independent AI which is feared by many doomsday preachers.

At PICANTE TECH Conference Europe (TCE2019), which will take place in Prague on the 3rd of September at Vienna House Andel’s Prague, we have put together an artificial intelligence-related panel discussion which will highlight some of the most recent topics that are discussed in the sphere and can benefit many in the upcoming period.

The panel discussion will be joined by Andjela Todorovic (Software Engineering Intern at Cubic Corporation), Jiří Třečák (CEO at Supernova), Aleksander Kijek (Chief Product Officer at Nethone) and last but not least, Vojtech Chloupek (Partner at Bird & Bird).

The futuristic thinking panel discussion will be moderated by Dr. Robert Skalina, Senior Advisor at WH Partners.

REGISTER HERE to secure your seat!

About Dr. Robert Skalina

Robert Skalina is a Czech Advocate as well as a Registered European Lawyer in Malta. He is based in Prague and works in Malta regularly.

He is financial services and corporate lawyer and provides advice to a wide range of investment managers, advisors and funds, including private equity and hedge funds. Robert also regularly advises clients in the gaming/gambling industries and has vast experience in the area of mergers and acquisitions and complex cross border transactions.

Robert has previously held the position of head of legal of a London based investment advisor active throughout the EMEA region. Prior to that, he served as legal counsel for the largest retail bank in the Czech Republic.

Robert graduated with an LLM cum laude from the London School of Economics. He holds a Master of Laws degree from the Charles University in Prague. He provides advice in English, Czech and Slovak.

PICANTE Tech Conference Europe is designed to bring both people and knowledge together and provides the excellent ecosystem of networking and learning opportunities without interruptions with emphasis on comfort and communication. After learning from genuine world-class experts and wayseers, meeting achievers shaping the B2B ecosystem, all attendees will get the chance to grab a drink and relax while networking at the evening social gathering.

REGISTER HERE or BROWSE THE AGENDA/PROGRAM!

Continue Reading

Artificial Intelligence

Artificial Solutions Wipes the Board with Four Podium Positions in Stevie 2019 International Business Awards Including Most Innovative Tech Company of the Year

Vlad Poptamas

Published

on

Photo source: aithority.com
Reading Time: 2 minutes

Artificial Solutions® (www.artificial-solutions.com), the leading specialist in enterprise-strength Conversational AI, announced today it has won awards in four Stevie® 2019 International Business Awards that were announced earlier today. The company was a Silver Stevie Winner in the prestigious Most Innovative Tech Company of the Year, Software Development Solution of the Year, and Artificial Intelligence/Machine Learning Solution of the Year. It was also a Bronze Stevie Winner in the IoT Analytics Solution category of the Awards.

The Stevie Awards are the world’s premier business awards. They were created in 2002 to honor and generate public recognition of the achievements and positive contributions of organizations and working professionals worldwide. In short order the Stevie has become one of the world’s most coveted prizes. The International Business Awards® (IBA) are open to all organizations worldwide: large and small, public and private, for-profit and non profit and attracted over 4000 entries.

“Recognition in any award is an honor. To win four International Stevies in four key tech-categories, including the highly contested Most Innovative Tech Company of the Year is amazing and a massive endorsement of the whole team at Artificial Solutions who have worked so hard to make Teneo an industry-leading solution,” comments Andy Peart, CMSO of Artificial Solutions.

Stevie Award winners were determined by the average scores of more than 250 executives worldwide who participated in the judging process from May through early August.

Most Innovative Tech Company of the Year recognizes overall achievement in product innovation. Artificial Solutions entry included the wide range of advanced enhancements made to Teneo in the last 12 months that has raised the bar for other conversational AI platforms. Judges commented that Teneo’s hybrid approach and broad support linguistic and lexical factors is truly impressive and that the company really streamlines the digital transformation journey using the sophisticated AI platform.

Teneo Developers, launched earlier this year, was honored for the best tool or resources for designing, creating or testing software applications. Judges for the Software Development Solution category commented that Visual UI platform to solve the problem of conversational UI is interesting. The problem being solved here could have very high returns.

Teneo’s revolutionary hybrid approach was awarded in the Artificial Intelligence/ Machine Learning category that recognizes solutions that enable computer-based systems to exhibit intelligent behavior in complex situations to solve problems, communicate with people, and perceive and interact with the physical world. Judges commented: Very impressed with how they combined classical ML with advanced NLP. Their use cases are great, and they managed to solve real and practical problems for companies.

The IoT Analytics Solution category recognized Teneo as one of the best applications for measuring and transforming Internet of Things (IoT) data into business intelligence. Judges commented that it showed Innovative use of cutting-edge technology and was a feature rich analytics solution while adhering data privacy laws.

The International Business Awards are the world’s premier business awards program. All individuals and organizations worldwide – public and private, for-profit and non-profit, large and small – are eligible to submit nominations. The 2019 IBAs received entries from organizations in 74 nations and territories.

Nicknamed the Stevies for the Greek word for “crowned,” the awards will be presented to winners at a gala awards banquet at the ANDAZ Hotel am Belvedere, Vienna, Austria on 19 October.

 

SOURCE Artificial Solutions International AB

Continue Reading

Artificial Intelligence

Aquaculture technology provider UMITRON launches Fish Appetite Index (FAI), the world’s first real-time ocean-based fish appetite detection system.

Vlad Poptamas

Published

on

Reading Time: 2 minutes

 

UMITRON PTE. LTD. (Singapore, Co-founder/ Managing Director Masahiko Yamada) launches Fish Appetite Index (FAI), the world’s first real-time ocean-based fish appetite detection system. UMITRON FAI uses efficient machine learning and image analysis techniques to extract relevant data from video streams that can then be used to accurately quantify fish appetite. FAI software has already been rolled out to existing customers to optimize their feeding operations.

Over the past twenty years the aquaculture industry has been expanding at an exponential rate with annual production tripling during this brief time span. At the same time, however, aquaculture feed prices have also risen dramatically. This presents an ever-growing challenge for farmers since feed costs account for a majority of their operational overhead. Farmers must walk a tight line: underfeeding their fish risks lower growth rates and slower time to market, while overfeeding increases costs and potentially harms the environment. New data analytics technologies such as IoT devices and machine learning offer farmers a solution to improve their feeding operations.

The FAI algorithm takes in the same visual information that humans would and then scores fish appetite and presents it in an easy to understand chart. When used in tandem with a smart feeder such as UMITRON CELL, the feed time intervals and amounts can be automatically adjusted with minimal human interference. Farm operators can utilize FAI to fine-tune their feeding schedules, ensuring fish are always satiated. This is easily done via their smartphones with the UMITRON app, where they can check and remotely adjust feed settings based on the FAI feedback.

FAI benefits farmers by reducing wasted feed, improving profitability as well as environmental sustainability. FAI in combination with technology such as CELL allows farmers to stay onshore during dangerous weather conditions or holidays while still keeping a close eye on their fish stocks. Furthermore, it reduces the need for every employee to be an expert at feeding and instead frees workers to focus on other tasks that improve fish welfare.

Existing UMITRON customers have already begun using FAI alongside CELL. “Today, there are many companies developing machine-learning algorithms for a variety of industries but only testing them under ideal conditions. The UMITRON Fish Appetite Index on the other hand is already being embraced by our existing customers at their ocean-based farm sites where it operates under real world conditions. It might be difficult for some of our potential customers to completely trust artificial intelligence at first, but FAI is an important tool that can be used to increase productivity and reduce waste,” said Masahiko Yamada, managing director of UMITRON.  “Our appetite analysis approach is being developed with customer feedback in mind. UMITRON will continue to develop similar value-added software services that can be automatically rolled out to our existing customer base. Also, we are open to developing other practical applications after discussions with potential customers or equipment partners,”  added Takuma Okamoto, CTO of UMITRON.

UMITRON is looking for partners interested in using FAI for species such as Atlantic salmon, rainbow trout, European sea bass, and gilthead sea bream. Similarly, UMITRON is looking for feeding system manufacturing partners who wish to utilize data analysis software such as FAI to improve their current products.

UMITRON will participate in AquaNor, which will be held in Trondheim, Norway from August 20-23, and The Japan International Seafood & Technology Expo from August 21-23 in Tokyo, Japan. Interested parties should contact UMITRON in advance to set up an informational meeting.

 

SOURCE Umitron

 

Continue Reading

Font Resizer

Subscribe to PICANTE via Email

Enter your email address to subscribe to PICANTE and receive notifications of new posts by email.

Follow us on Facebook

Read more from our authors

Follow our Tweets

Trending

Please turn AdBlock off